Home Healthcare Pharmaceuticals Endometriosis Treatment Market

Endometriosis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Hormonal Therapy, Non-Hormonal Therapy), By Route of Administration (Oral, Injectables, Nasal, Others (e.g., implants, transdermal patches)), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 26, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Endometriosis Treatment Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Hormonal Therapy
      1. Gonadotropin-Releasing Hormone (GnRH) Agonists
      2. Oral Contraceptives
      3. Progestins
      4. Danazol
    2. Non-Hormonal Therapy
      1. NSAIDs
      2. Analgesics
  2. Endometriosis Treatment Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectables
    3. Nasal
    4. Others (e.g., implants, transdermal patches)
  3. Endometriosis Treatment Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital pharmacy
    2. Retail pharmacy
    3. Others
  4. Regional Endometriosis Treatment Market
    1. North America
      1. North America Endometriosis Treatment Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
      2. North America Endometriosis Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectables
        3. Nasal
        4. Others (e.g., implants, transdermal patches)
      3. North America Endometriosis Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacy
        2. Retail pharmacy
        3. Others
      4. U.S.
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      5. Canada
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
    2. Europe
      1. Europe Endometriosis Treatment Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
      2. Europe Endometriosis Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectables
        3. Nasal
        4. Others (e.g., implants, transdermal patches)
      3. Europe Endometriosis Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacy
        2. Retail pharmacy
        3. Others
      4. U.K.
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      5. Germany
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      6. France
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      7. Spain
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      8. Italy
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      9. Russia
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      10. Nordic
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      11. Benelux
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      12. Rest of Europe
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
    3. APAC
      1. APAC Endometriosis Treatment Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
      2. APAC Endometriosis Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectables
        3. Nasal
        4. Others (e.g., implants, transdermal patches)
      3. APAC Endometriosis Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacy
        2. Retail pharmacy
        3. Others
      4. China
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      5. Korea
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      6. Japan
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      7. India
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      8. Australia
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      9. Taiwan
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      10. South East Asia
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      11. Rest of Asia-Pacific
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
    4. Middle East and Africa
      1. Middle East and Africa Endometriosis Treatment Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
      2. Middle East and Africa Endometriosis Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectables
        3. Nasal
        4. Others (e.g., implants, transdermal patches)
      3. Middle East and Africa Endometriosis Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacy
        2. Retail pharmacy
        3. Others
      4. UAE
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      5. Turkey
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      6. Saudi Arabia
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      7. South Africa
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      8. Egypt
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      9. Nigeria
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      10. Rest of MEA
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
    5. LATAM
      1. LATAM Endometriosis Treatment Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
      2. LATAM Endometriosis Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectables
        3. Nasal
        4. Others (e.g., implants, transdermal patches)
      3. LATAM Endometriosis Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacy
        2. Retail pharmacy
        3. Others
      4. Brazil
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      5. Mexico
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      6. Argentina
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      7. Chile
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      8. Colombia
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
      9. Rest of LATAM
        1. Hormonal Therapy
          1. Gonadotropin-Releasing Hormone (GnRH) Agonists
          2. Oral Contraceptives
          3. Progestins
          4. Danazol
        2. Non-Hormonal Therapy
          1. NSAIDs
          2. Analgesics
        3. Oral
        4. Injectables
        5. Nasal
        6. Others (e.g., implants, transdermal patches)
        7. Hospital pharmacy
        8. Retail pharmacy
        9. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.